Drug intelligence / Profile preview

DBT-05

Development stage: Preclinical
Lead developer: Discovery Biotech

Overview

DBT-05 is an investigational therapeutic candidate currently in the discovery stage of development by Discovery Biotech. The program is part of a broader pipeline aimed at addressing the challenge of therapy resistance in cancer, which often arises from genetic mutations, metabolic alterations, or microenvironmental shifts. As of early 2024, specific details regarding the drug's molecular target, modality, and precise mechanism of action remain proprietary and have not been publicly disclosed.

Beyond the preview

Go deeper on DBT-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DBT-05.

Explore the full profile